

Q³ [Please substitute the following claim 21 for the pending claim 21:]

21. (once amended) A nucleic acid molecule comprising, a first polynucleotide that hybridizes to a second polynucleotide, wherein said second polynucleotide is complementary to the nucleic acid molecule of claims 15, 16, or 17.

Please substitute the following claim 28 for the pending claim 28:

Q⁴ 28. (once amended) A pharmaceutical composition comprising the anti-LRP-A β peptide of claims 4, 5, 6 or 13, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

Please substitute the following claim 32 for the pending claim 32:

Q⁵ 32. (once amended) A method of combating Alzheimer's Disease in a subject comprising administering the anti-LRP-A β peptide of claims 4, 5, 6 or 13, or a pharmaceutically acceptable salt thereof.

Please substitute the following claim 47 for the pending claim 47:

47. (once amended) The viral vector of claim 43, wherein said transgene encodes the anti-LRP-A β peptide of claims 4, 5, 6, 12 or 13.

[Please substitute the following claim 48 for the pending claim 48:]

Q⁶ 48. (once amended) The viral vector of claims 43, 44, 45, or 46, wherein said viral vector is an adeno-associated virus.

[Please substitute the following claim 49 for the pending claim 49:]

49. (once amended) A pharmaceutical composition comprising the viral vector of claims 43, 44, 45, or 46, and one or more pharmaceutically acceptable carriers.

[Please substitute the following claim 50 for the pending claim 50:]

50. (once amended) A method of combating Alzheimer's Disease in a subject by administering the viral vector of claims 43, 44, 45, or 46.